Beclomethasone (inhaled, nasal)

A corticosteroid inhaled for long-term asthma control or sprayed in the nose for seasonal and year-round allergic rhinitis.

psilodex.org/m/beclomethasone · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~2.8–4 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Beclomethasone (inhaled, nasal)”, v2026.10.05. psilodex.org/m/beclomethasone

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Maintenance treatment of asthma (ages 4 and up)
Nasal symptoms of seasonal and year-round allergic rhinitis (ages 4 and up)

Sources [1][2]

01 Interaction with psilocybin

This inhaled or nasal steroid has no known interaction with psilocybin.

Detail Beclomethasone is an inhaled or nasal steroid with no known interaction with psilocybin.

Human data with psilocybin: No psilocybin data; based on its label
Half-life: ~2.8–4 h (active metabolite) (FDA label, checked 2026-10-04) Beclomethasone-17-monopropionate: about 4 h (Qvar RediHaler), 2.8 h (Qnasl).

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Asthma or COPD (provision applies if severe or unstable)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

QVAR REDIHALER (beclomethasone dipropionate HFA) inhalation aerosol (Teva) · FDA label (DailyMed) — Indications: "maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older" | "The mean terminal half-life of 17-BMP is approximately 4 hours for QVAR REDIHALER."
QNASL (beclomethasone dipropionate) nasal aerosol (Teva) · FDA label (DailyMed) — Indications 1.1 "treatment of the nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older" | "The mean elimination half-life of beclomethasone-17-monopropionate is 2.8 hours."
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →